Results 21 to 30 of about 3,389 (131)

Interpretation of Key Updates in the 36th Edition of Clinical and Laboratory Standards Institute M100 Standard

open access: yesiLABMED, Volume 4, Issue 3, Page 133-138, September 2026.
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley   +1 more source

AmpC β-lactamase induction by avibactam and relebactam [PDF]

open access: yes, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Neil Woodford   +11 more
core   +1 more source

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou   +6 more
wiley   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari   +2 more
wiley   +1 more source

Emergence of Ceftazidime‐Avibactam‐Induced KPC Variants (KPC‐25/127) in Intracranial Infection and Implications for Clinical Management

open access: yesMicrobiologyOpen, Volume 15, Issue 4, August 2026.
Novel KPC‐25 and first‐reported KPC‐127 sequentially evolved in one patient under CAZ‐AVI pressure, distinct mutations remodel enzyme activity to drive differential multidrug resistance. ABSTRACT The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public ...
Ke Lei   +8 more
wiley   +1 more source

Role of Relebactam in the Antibiotic Resistance Acquisition in Pseudomonas aeruginosa: In Vitro Study

open access: yes, 2023
Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Esperanza Merino   +8 more
core   +1 more source

Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence

open access: yesMicrobiologyOpen, Volume 15, Issue 3, June 2026.
Phage therapy shows promising efficacy against MDR, XDR, and PDR Pseudomonas aeruginosa infections across different models and administration routes. Evidence highlights reduced mortality, bacterial clearance, and synergy with antibiotics, while emphasizing the need for standardized protocols and advanced delivery systems to support clinical ...
Gustavo Aparecido da Cunha   +7 more
wiley   +1 more source

The evolving role of structural biology in pharma: integration of X‐ray crystallography, cryo‐electron microscopy and beyond

open access: yesActa Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik   +44 more
wiley   +1 more source

Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies

open access: yesClinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley   +1 more source

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections [PDF]

open access: yes, 2021
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and
Lagnf, Abdalhamid M.   +19 more
core   +1 more source

Home - About - Disclaimer - Privacy